Ligand Pharma (LGND) Tops Q4 EPS by 17c
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $50.5 million versus the consensus estimate of $47.82 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.